Development of Multiple Facial Lipomas During Immunotherapy for Metastatic Squamous Cell Carcinoma

Main Article Content

Kathryn Hall
BCOM

Adrian Guevara

Keywords

immunotherapy, lipoma, Adipogenesis, Immune Checkpoint Inhibitors, PD-1 Inhibitor, Pembrolizumab, Tertiary Lymph Structure

Abstract

An 85-year-old Caucasian male on immunotherapy for metastatic squamous cell carcinoma presented with enlarging lipomas in the area of his previous invasive squamous cell carcinoma of the lower lip and chin, status post resection, reconstruction and local radiation.  The development of multiple lipomas during immunotherapy is a novel association which has yet to be reported in the literature.  We discuss a putative mechanism of action of pembrolizumab-induced lipomas and describe the patient's clinical course.

References

1. Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535. PMID: 31050774; PMCID: PMC6503493.

2. Laba, S., Mallett, G. & Amarnath, S. The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells. Semin. Cancer Biol. https://doi.org/10.1016/j.semcancer.2021.05.022 (2021).

3. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014 Oct 16;41(4):529-42. doi: 10.1016/j.immuni.2014.10.004. PMID: 25367570; PMCID: PMC4223692.

4. Sautès-Fridman, C., Petitprez, F., Calderaro, J. et al. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 19, 307–325 (2019). https://doi.org/10.1038/s41568-019-0144-6

5. Gao SH, Liu SZ, Wang GZ, Zhou GB. CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities. Life (Basel). 2021 Nov 23;11(12):1282. doi: 10.3390/life11121282. PMID: 34947813; PMCID: PMC8708574.

6. Kusuyama J, Bandow K, Ohnishi T, Amir MS, Shima K, Semba I, Matsuguchi T. CXCL13 is a differentiation- and hypoxia-induced adipocytokine that exacerbates the inflammatory phenotype of adipocytes through PHLPP1 induction. Biochem J. 2019 Nov 29;476(22):3533-3548. doi: 10.1042/BCJ20190709. PMID: 31710352.

7. Kazanietz M, Durando M, Cooke M. CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond. Frontiers in Endocrinology. 2019 (10). doi: 10.3389/fendo.2019.00471. ISSN: 1664-2392.

8. Syeda M Kabir, Eun-Sook Lee & Deok-Soo Son (2014) Chemokine network during adipogenesis in 3T3-L1 cells,Adipocyte, 3:2, 97-106, DOI: 10.4161/adip.28110

9. Hsieh CH, Jian CZ, Lin LI, Low GS, Ou PY, Hsu C, Ou DL. Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. Cancers (Basel). 2022 Jan 7;14(2):294. doi: 10.3390/cancers14020294. PMID: 35053457; PMCID: PMC8774093.

10. Charifa A, Azmat CE, Badri T. Lipoma Pathology. [Updated 2022 Dec 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482343/

11. Aust MC, Spies M, Kall S, Jokuszies A, Gohritz A, Vogt P. Posttraumatic lipoma: fact or fiction? Skinmed. 2007 Nov-Dec;6(6):266-70. doi: 10.1111/j.1540-9740.2007.06361.x. PMID: 17975353.

12. Kang J, Botros M, Goldberg S, Giraud C, Nielsen GP, Chen YL, Raskin K, Schwab J, Yoon SS, Hornicek FJ, Delaney TF. The use of radiation therapy in the management of selected patients with atypical lipomas. Sarcoma. 2013;2013:485483. doi: 10.1155/2013/485483. Epub 2013 Jan 15. PMID: 23401663; PMCID: PMC3562577.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.6.21

Article Details

How to Cite
Hall, K., & Guevara, A. (2023). Development of Multiple Facial Lipomas During Immunotherapy for Metastatic Squamous Cell Carcinoma. SKIN The Journal of Cutaneous Medicine, 7(6), 1195–1198. https://doi.org/10.25251/skin.7.6.21
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)